Center Laboratories, Inc. (4123.TWO)
TWD 41.9
(-1.53%)
TWD 41.9
(-1.53%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.42 Billion TWD | 243.6% |
| 2022 | 1.28 Billion TWD | -64.94% |
| 2021 | 3.67 Billion TWD | 106.78% |
| 2020 | 1.77 Billion TWD | 10.39% |
| 2019 | 1.61 Billion TWD | -26.22% |
| 2018 | 2.18 Billion TWD | -43.16% |
| 2017 | 3.83 Billion TWD | 43.54% |
| 2016 | 2.67 Billion TWD | -43.08% |
| 2015 | 4.7 Billion TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | -100.0% |
| 2011 | 92.68 Million TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | -100.0% |
| 2008 | 267.69 Million TWD | 0.0% |
| 2007 | - TWD | 0.0% |
| 2006 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 5.71 Billion TWD | 29.56% |
| 2024 Q2 | 5.68 Billion TWD | -0.54% |
| 2023 Q1 | 94.21 Million TWD | -92.69% |
| 2023 Q3 | 4.39 Billion TWD | 63.99% |
| 2023 Q4 | 4.42 Billion TWD | 0.76% |
| 2023 FY | 4.42 Billion TWD | 243.6% |
| 2023 Q2 | 2.68 Billion TWD | 2745.01% |
| 2022 Q2 | 1.84 Billion TWD | -23.14% |
| 2022 Q4 | 1.28 Billion TWD | 0.0% |
| 2022 FY | 1.28 Billion TWD | -64.94% |
| 2022 Q1 | 2.4 Billion TWD | -34.69% |
| 2022 Q3 | 1.28 Billion TWD | -30.15% |
| 2021 Q4 | 3.67 Billion TWD | 18.33% |
| 2021 FY | 3.67 Billion TWD | 106.78% |
| 2021 Q1 | 1.78 Billion TWD | 0.61% |
| 2021 Q2 | 2.94 Billion TWD | 64.55% |
| 2021 Q3 | 3.1 Billion TWD | 5.55% |
| 2020 Q3 | 1.76 Billion TWD | 295.04% |
| 2020 Q4 | 1.77 Billion TWD | 0.62% |
| 2020 Q2 | 447.27 Million TWD | -72.12% |
| 2020 Q1 | 1.6 Billion TWD | -0.4% |
| 2020 FY | 1.77 Billion TWD | 10.39% |
| 2019 FY | 1.61 Billion TWD | -26.22% |
| 2019 Q3 | 1.62 Billion TWD | -43.68% |
| 2019 Q2 | 2.89 Billion TWD | 15.32% |
| 2019 Q1 | 2.5 Billion TWD | 14.89% |
| 2019 Q4 | 1.61 Billion TWD | -1.12% |
| 2018 Q2 | 771.11 Million TWD | -79.44% |
| 2018 Q1 | 3.74 Billion TWD | -2.35% |
| 2018 FY | 2.18 Billion TWD | -43.16% |
| 2018 Q4 | 2.18 Billion TWD | 7.59% |
| 2018 Q3 | 2.02 Billion TWD | 163.11% |
| 2017 Q3 | 3.53 Billion TWD | 2.19% |
| 2017 Q2 | 3.45 Billion TWD | 34.24% |
| 2017 Q1 | 2.57 Billion TWD | -3.71% |
| 2017 FY | 3.83 Billion TWD | 43.54% |
| 2017 Q4 | 3.83 Billion TWD | 8.67% |
| 2016 Q3 | 2.84 Billion TWD | -42.75% |
| 2016 FY | 2.67 Billion TWD | -43.08% |
| 2016 Q1 | 4.94 Billion TWD | 5.27% |
| 2016 Q2 | 4.97 Billion TWD | 0.6% |
| 2016 Q4 | 2.67 Billion TWD | -6.12% |
| 2015 Q4 | 4.7 Billion TWD | 59.91% |
| 2015 FY | 4.7 Billion TWD | 0.0% |
| 2015 Q3 | 2.93 Billion TWD | 85.52% |
| 2015 Q2 | 1.58 Billion TWD | 540.13% |
| 2015 Q1 | 247.5 Million TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q4 | - TWD | 0.0% |
| 2014 Q3 | - TWD | 0.0% |
| 2014 Q2 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2012 Q2 | - TWD | -100.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 Q1 | 93.4 Million TWD | 0.77% |
| 2012 FY | - TWD | -100.0% |
| 2011 Q3 | 91.97 Million TWD | 0.78% |
| 2011 Q1 | 90.54 Million TWD | 0.0% |
| 2011 Q2 | 91.25 Million TWD | 0.79% |
| 2011 Q4 | 92.68 Million TWD | 0.78% |
| 2011 FY | 92.68 Million TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | -100.0% |
| 2008 FY | 267.69 Million TWD | 0.0% |
| 2007 FY | - TWD | 0.0% |
| 2006 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Allied Biotech Corporation | 72.02 Million TWD | -6049.407% |
| GeneFerm Biotechnology Co., Ltd. | 76.14 Million TWD | -5716.293% |
| Easywell Biomedicals, Inc. | 330.44 Million TWD | -1240.316% |
| TTY Biopharm Company Limited | 403.04 Million TWD | -998.891% |
| Synmosa Biopharma Corporation | 1.45 Billion TWD | -203.63% |
| Orient EuroPharma Co., Ltd. | 2.2 Billion TWD | -101.048% |
| Tien Liang BioTech Co., Ltd. | 377 Thousand TWD | -1174714.058% |
| Orient Pharma Co., Ltd. | 323.73 Million TWD | -1268.114% |
| InnoPharmax Inc. | 5.38 Million TWD | -82132.622% |
| Johnson Chemical Pharmaceutical Works Co., Ltd. | 100.83 Million TWD | -4292.547% |
| Excelsior Biopharma Inc. | 300.25 Million TWD | -1375.12% |
| DV Biomed Co., Ltd. | 315.74 Million TWD | -1302.712% |
| Foresee Pharmaceuticals Co., Ltd. | 13.11 Million TWD | -33670.865% |
| Handa Pharmaceuticals, Inc. | 7.67 Million TWD | -57637.57% |
| UniPharma Co., Ltd. | - TWD | -Infinity% |
| Anxo Pharmaceutical Co., Ltd. | 499.69 Million TWD | -786.35% |
| Alar Pharmaceuticals Inc. | 138 Thousand TWD | -3209355.797% |
| Winston Medical Supply Co., Ltd. | 56.05 Million TWD | -7800.974% |
| Mercury Biopharmaceutical Corporation | 41.66 Million TWD | -10529.377% |
| Bioray Biotech Co., Ltd | 65.65 Million TWD | -6645.943% |
| TSH Biopharm Corporation Limited | - TWD | -Infinity% |